BioScrip Reports Second Quarter 2017 Financial Results
– Net revenue of
– Net loss from continuing operations of
– Adjusted EBITDA of
– Operating Cash Flow of
– Liquidity of
– Restructuring expenses of
– The Company reaffirms EBITDA guidance and updates revenue guidance
“The second quarter of
2017 Guidance
The Company is reiterating its prior guidance of adjusted EBITDA in the range of
Conference Call and Presentation
A replay of the conference call will be available for two weeks after the call's completion by dialing 855-859-2056 (US) and entering conference call ID number 51901836. An audio webcast and archive will also be available for 30 days under the "Investor Relations" section of the Company's website.
About
Forward-Looking Statements – Safe Harbor
This press release includes statements that may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the statements regarding 2017 guidance, projections of certain measures of the Company's results of operations, projections of future levels of certain charges and expenses, expectations of Home Solutions cost synergies and incremental cost structure improvements and other statements regarding the Company's financial improvement plan and strategy and anticipated effects of the Cures Act and the UnitedHealthcare contract. You can identify these statements by the fact that they do not relate strictly to historical or current facts. In some cases, forward-looking statements can be identified by words such as "may," "should," "could," "anticipate," "estimate," "expect," "project," "outlook," "aim," "intend," "plan," "believe," "predict," "potential," "continue" or comparable terms. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Important factors that could cause actual results to differ materially from those in the forward-looking statement include but are not limited to risks associated with: the Company’s ability to successfully integrate the Home Solutions business into its existing businesses; the Company’s ability to grow its core Infusion revenues; the Company's ability to continue to execute its financial improvement plan to reduce operating costs and focus its business on its Infusion Services segment; the Company’s ability to evaluate opportunities for improvement and implement solutions as part of its strategic review process; the Company’s ability to comply with the covenants in its debt agreements or obtain amendments to such covenants; the UnitedHealthcare contract termination, including potential accounting charges and impacts on other contract provisions and their associated revenue; the success of the Company’s initiatives to mitigate the impact of the Cures Act on its business; reductions in federal, state and commercial reimbursement for the Company's products and services; increased government regulation related to the health care and insurance industries; as well as the risks described in the Company's periodic filings with the
Note Regarding Use of Non-GAAP Financial Measures
In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the Company’s liquidity. In addition, the Company's definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation and amortization, impairment of goodwill, stock-based compensation expense, and restructuring, integration and other expenses. As part of restructuring, the Company may incur significant charges such as the write down of certain long−lived assets, temporary redundant expenses, retraining expenses, potential cash bonus payments and potential accelerated payments or terminated costs for certain of its contractual obligations. Management believes that Adjusted EBITDA provides useful supplemental information regarding the performance of BioScrip’s business operations and facilitates comparisons to the Company’s historical operating results. For a full reconciliation of Adjusted EBITDA to the most comparable GAAP financial measure, please see the attachment to this earnings release.
Schedule 1 | |||||||
BIOSCRIP, INC. AND SUBSIDIARIES | |||||||
CONSOLIDATED BALANCE SHEETS | |||||||
(in thousands, except for share amounts) | |||||||
June 30, 2017 | December 31, 2016 | ||||||
ASSETS | |||||||
Current assets | |||||||
Cash and cash equivalents | $ | 40,533 | $ | 9,569 | |||
Restricted cash | 5,055 | - | |||||
Receivables, less allowance for doubtful accounts of $45,651 and $44,730 | |||||||
as of June 30, 2017 and December 31, 2016, respectively | 103,089 | 111,811 | |||||
Inventory | 28,822 | 36,165 | |||||
Prepaid expenses and other current assets | 12,998 | 18,507 | |||||
Total current assets | 190,497 | 176,052 | |||||
Property and equipment, net | 30,063 | 32,535 | |||||
Goodwill | 365,947 | 365,947 | |||||
Intangible assets, net | 24,672 | 31,043 | |||||
Other non-current assets | 2,204 | 2,163 | |||||
Total assets | $ | 613,383 | $ | 607,740 | |||
LIABILITIES AND STOCKHOLDERS' DEFICIT | |||||||
Current liabilities | |||||||
Current portion of long-term debt | $ | 1,731 | $ | 18,521 | |||
Accounts payable | 46,381 | 59,134 | |||||
Amounts due to plan sponsors | 4,825 | 3,799 | |||||
Accrued interest | 6,736 | 6,705 | |||||
Accrued expenses and other current liabilities | 43,209 | 42,191 | |||||
Total current liabilities | 102,882 | 130,350 | |||||
Long-term debt, net of current portion | 475,674 | 433,413 | |||||
Deferred taxes | 3,504 | 2,281 | |||||
Other non-current liabilities | 17,942 | 1,257 | |||||
Total liabilities | 600,002 | 567,301 | |||||
Series A convertible preferred stock, $.0001 par value; 825,000 shares authorized; | |||||||
21,645 shares issued and outstanding as of June 30, 2017 and December 31, 2016; | |||||||
and $2,754 and $2,603 liquidation preference as of June 30, 2017 and | |||||||
December 31, 2016, respectively | 2,639 | 2,462 | |||||
Series C convertible preferred stock, $.0001 par value; 625,000 shares authorized; | |||||||
614,177 shares issued and outstanding as of June 30, 2017 and December 31, 2016; | |||||||
and $79,858 and $75,491 liquidation preference as of June 30, 2017 and | |||||||
December 31, 2016, respectively | 74,229 | 69,540 | |||||
Stockholders' (deficit) equity | |||||||
Preferred stock, $.0001 par value; 5,000,000 shares authorized; no shares issued and | |||||||
outstanding as of June 30, 2017 and December 31, 2016, respectively | - | - | |||||
Common stock, $.0001 par value; 250,000,000 shares authorized; 127,441,893 and | |||||||
117,682,543 shares issued and outstanding as of June 30, 2017 and | |||||||
December 31, 2016, respectively | 13 | 12 | |||||
Additional paid-in capital | 628,545 | 611,844 | |||||
Accumulated deficit | (692,045 | ) | (643,419 | ) | |||
Total stockholders' deficit | (63,487 | ) | (31,563 | ) | |||
Total liabilities and stockholders' deficit | $ | 613,383 | $ | 607,740 | |||
Schedule 2 | ||||||||||||||||||
BIOSCRIP, INC. AND SUBSIDIARIES | ||||||||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||||
(in thousands, except per share amounts) | ||||||||||||||||||
Three Months Ended June 30, | Six Months Ending June 30, | |||||||||||||||||
2017 | 2016 | 2017 | 2016 | |||||||||||||||
Net revenue | $ | 218,106 | $ | 232,462 | $ | 435,916 | $ | 470,924 | ||||||||||
Cost of revenue (excluding depreciation expense) | 149,796 | 168,298 | 302,022 | 342,528 | ||||||||||||||
Gross profit | 68,310 | 64,164 | 133,894 | 128,396 | ||||||||||||||
% of revenues | 31.3 | % | 27.6 | % | 30.7 | % | 27.3 | % | ||||||||||
Other operating expenses | 42,486 | 40,619 | 86,844 | 80,277 | ||||||||||||||
Bad debt expense | 6,223 | 4,279 | 13,387 | 11,871 | ||||||||||||||
General and administrative expenses | 10,025 | 9,414 | 19,504 | 20,465 | ||||||||||||||
Restructuring, acquisition, integration, and other expenses, net | 3,911 | 4,291 | 7,134 | 6,958 | ||||||||||||||
Depreciation and amortization expense | 6,789 | 4,252 | 13,777 | 8,790 | ||||||||||||||
Interest expense | 12,715 | 9,469 | 25,459 | 18,881 | ||||||||||||||
Loss on extinguishment of debt | 13,453 | - | 13,453 | - | ||||||||||||||
Loss (gain) on dispositions | 685 | - | 685 | (939 | ) | |||||||||||||
Loss from continuing operations, before income taxes | (27,977 | ) | (8,160 | ) | (46,349 | ) | (17,907 | ) | ||||||||||
Income tax expense | 718 | 149 | 1,337 | 172 | ||||||||||||||
Loss from continuing operations, net of income taxes | (28,695 | ) | (8,309 | ) | (47,686 | ) | (18,079 | ) | ||||||||||
(Loss) income from discontinued operations, net of income taxes | (503 | ) | 75 | (940 | ) | 308 | ||||||||||||
Net loss | $ | (29,198 | ) | $ | (8,234 | ) | $ | (48,626 | ) | $ | (17,771 | ) | ||||||
Accrued dividends on preferred stock | (2,303 | ) | (2,056 | ) | (4,517 | ) | (4,054 | ) | ||||||||||
Deemed dividend on preferred stock | (175 | ) | (173 | ) | (349 | ) | (345 | ) | ||||||||||
Loss attributable to common stockholders | $ | (31,676 | ) | $ | (10,463 | ) | $ | (53,492 | ) | $ | (22,170 | ) | ||||||
Denominator - Basic and Diluted: | ||||||||||||||||||
Weighted average number of common shares outstanding | 121,189 | 73,186 | 119,993 | 70,978 | ||||||||||||||
Loss from continuing operations, basic and diluted | $ | (0.26 | ) | $ | (0.14 | ) | $ | (0.44 | ) | $ | (0.32 | ) | ||||||
Income from discontinued operations, basic and diluted | - | - | (0.01 | ) | - | |||||||||||||
Loss per common share, basic and diluted | $ | (0.26 | ) | $ | (0.14 | ) | $ | (0.45 | ) | $ | (0.32 | ) | ||||||
Schedule 3 | ||||||||||||||||
BIOSCRIP, INC. AND SUBSIDIARIES | ||||||||||||||||
QUARTERLY RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES | ||||||||||||||||
(in thousands) | ||||||||||||||||
Three Months Ended |
Six Months Ended | |||||||||||||||
6/30/2017 | 6/30/2016 | 6/30/2017 | 6/30/2016 | |||||||||||||
Adjusted EBITDA by Segment: | ||||||||||||||||
Infusion Services Adjusted EBITDA | $ | 19,601 | $ | 19,266 | $ | 33,663 | $ | 36,248 | ||||||||
Adjusted EBITDA margin % | 9.0 | % | 8.3 | % | 7.7 | % | 7.7 | % | ||||||||
Corporate Overhead Adjusted EBITDA | (9,592 | ) | (8,895 | ) | (18,477 | ) | (18,472 | ) | ||||||||
Adjusted EBITDA margin % | (4.4 | %) | (3.8 | %) | (4.2 | %) | (3.9 | %) | ||||||||
Consolidated Adjusted EBITDA | 10,009 | 10,371 | 15,186 | 17,776 | ||||||||||||
Adjusted EBITDA margin % | 4.6 | % | 4.5 | % | 3.5 | % | 3.8 | % | ||||||||
Interest expense | (12,715 | ) | (9,469 | ) | (25,459 | ) | (18,881 | ) | ||||||||
(Loss) gain on dispositions | (685 | ) | - | (685 | ) | 939 | ||||||||||
Loss on extinguishment of debt | (13,453 | ) | - | (13,453 | ) | - | ||||||||||
Income tax expense | (718 | ) | (149 | ) | (1,337 | ) | (172 | ) | ||||||||
Depreciation and amortization expense | (6,789 | ) | (4,252 | ) | (13,777 | ) | (8,790 | ) | ||||||||
Stock-based compensation expense | (433 | ) | (519 | ) | (1,027 | ) | (1,993 | ) | ||||||||
Restructuring, acquisition, integration, and other expenses, net (1) | (3,911 | ) | (4,291 | ) | (7,134 | ) | (6,958 | ) | ||||||||
Loss from continuing operations, net of income taxes | $ | (28,695 | ) | $ | (8,309 | ) | $ | (47,686 | ) | $ | (18,079 | ) | ||||
General and Administrative Expenses on Face of Income Statement: | ||||||||||||||||
Corporate overhead adjusted EBITDA | $ | (9,592 | ) | $ | (8,895 | ) | $ | (18,477 | ) | $ | (18,472 | ) | ||||
Stock-based compensation (expense) | (433 | ) | (519 | ) | (1,027 | ) | (1,993 | ) | ||||||||
General and administrative expenses | $ | (10,025 | ) | $ | (9,414 | ) | $ | (19,504 | ) | $ | (20,465 | ) | ||||
(1) Restructuring, acquisition, integration and other expenses, net include costs associated with restructuring, acquisition, and integration initiatives such as employee severance costs, certain legal and professional fees, redundant wage costs, impacts recorded from the change in contingent consideration obligations, and other costs related to contract terminations and closed locations. | ||||||||||||||||
Schedule 4 | ||||||||||||||||||||||||
BIOSCRIP, INC AND SUBSIDIARIES | ||||||||||||||||||||||||
CONSOLIDATED CONDENSED CASH FLOWS | ||||||||||||||||||||||||
(in thousands) | ||||||||||||||||||||||||
Three Months Ended | Six Months Ended | Three Months Ended | Six Months Ended | |||||||||||||||||||||
3/31/2017 | 6/30/2017 | 6/30/2017 | 3/31/2016 | 6/30/2016 | 6/30/2016 | |||||||||||||||||||
Cash flows from operating activities: | ||||||||||||||||||||||||
Net loss from continuing operations | $ | (18,991 | ) | $ | (28,695 | ) | $ | (47,686 | ) | $ | (9,770 | ) | $ | (8,309 | ) | $ | (18,079 | ) | ||||||
Receivables, net of bad debt expense | 2,333 | 6,388 | 8,721 | (4,417 | ) | 3,136 | (1,281 | ) | ||||||||||||||||
Inventory | 5,616 | 1,727 | 7,343 | 13,867 | (3,330 | ) | 10,537 | |||||||||||||||||
Prepaid expenses and other assets | 3,601 | 1,868 | 5,469 | 7,897 | (7,575 | ) | 322 | |||||||||||||||||
Accounts payable | (11,688 | ) | (1,065 | ) | (12,753 | ) | (11,995 | ) | (4,195 | ) | (16,190 | ) | ||||||||||||
Accrued interest | (1,157 | ) | 1,188 | 31 | (4,630 | ) | 4,438 | (192 | ) | |||||||||||||||
Accrued expenses and other liabilities | 244 | 1,497 | 1,741 | (2,227 | ) | (851 | ) | (3,078 | ) | |||||||||||||||
Non-Cash Adjustments: | ||||||||||||||||||||||||
Depreciation and amortization | 6,988 | 6,789 | 13,777 | 4,538 | 4,252 | 8,790 | ||||||||||||||||||
Loss on extinguishment of debt | - | 13,453 | 13,453 | - | - | - | ||||||||||||||||||
Deferred taxes | 619 | 604 | 1,223 | 174 | 178 | 352 | ||||||||||||||||||
Other Non-Cash | 1,839 | 2,748 | 4,587 | 1,589 | 1,554 | 3,143 | ||||||||||||||||||
Operating Cash Flow (Use) | (10,596 | ) | 6,502 | (4,094 | ) | (4,974 | ) | (10,702 | ) | (15,676 | ) | |||||||||||||
Discontinued operations | (437 | ) | (503 | ) | (940 | ) | (5,989 | ) | 76 | (5,913 | ) | |||||||||||||
Capital expenditures | (1,684 | ) | (2,608 | ) | (4,292 | ) | (2,429 | ) | (3,037 | ) | (5,466 | ) | ||||||||||||
Investment in restricted cash | (5,132 | ) | 77 | (5,055 | ) | - | 27 | 27 | ||||||||||||||||
Proceeds from dispositions | - | - | - | 1,105 | - | 1,105 | ||||||||||||||||||
Proceeds from equity offering, net | - | - | - | - | 83,267 | 83,267 | ||||||||||||||||||
Proceeds from priming credit agreement, net of expenses | 23,060 | - | 23,060 | - | - | - | ||||||||||||||||||
Fees attributable to extinguishment of debt | - | (311 | ) | (311 | ) | - | - | - | ||||||||||||||||
Net proceeds from equity issuance, net of issuance costs | 5,052 | 15,724 | 20,776 | - | - | - | ||||||||||||||||||
Proceeds from borrowing on long-term debt | 563 | 293,883 | 294,446 | - | - | - | ||||||||||||||||||
Principal payments of long-term debt | (3,137 | ) | (233,633 | ) | (236,770 | ) | (3,137 | ) | (3,137 | ) | (6,274 | ) | ||||||||||||
Revolver borrowings (repayments) | (1,000 | ) | (54,300 | ) | (55,300 | ) | 8,000 | (23,000 | ) | (15,000 | ) | |||||||||||||
Other | (289 | ) | (267 | ) | (556 | ) | (104 | ) | (118 | ) | (222 | ) | ||||||||||||
Total All Cash Flow | $ | 6,400 | $ | 24,564 | $ | 30,964 | $ | (7,528 | ) | $ | 43,376 | $ | 35,848 | |||||||||||
Schedule 5 | |||||||
BIOSCRIP, INC AND SUBSIDIARIES | |||||||
FULL YEAR 2017 GUIDANCE | |||||||
(dollars in millions, except EPS) | |||||||
Low End | High End | ||||||
of Range | of Range | ||||||
Revenues | $ | 815.0 | $ | 835.0 | |||
Adjusted EBITDA | 45.0 | 55.0 | |||||
adjusted ebitda margin | 4.9 | % | 5.8 | % | |||
Stock Compensation | 3.0 | 2.5 | |||||
Depreciation & Amortization | 27.0 | 25.0 | |||||
Interest Expense, net | 52.0 | 49.0 | |||||
Restructuring Costs | 12.0 | 11.0 | |||||
Income Tax Expense | 3.0 | 2.0 | |||||
Preferred Stock Dividends | 9.4 | 9.4 | |||||
Net Loss - Continuing Ops | $ | (61.4 | ) | $ | (43.9 | ) | |
Diluted Loss Per Common Share | $ | (0.51 | ) | $ | (0.36 | ) | |
weighted-average diluted shares | 121,000 | 121,000 |
Schedule 6 | ||||||||||||
BIOSCRIP, INC. AND SUBSIDIARIES | ||||||||||||
QUARTERLY CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||
(in thousands, except per share amounts) | ||||||||||||
Three Months Ended | Six Months Ended | |||||||||||
3/31/2017 | 6/30/2017 | 6/30/2017 | ||||||||||
Net revenue | $ | 217,810 | $ | 218,106 | $ | 435,916 | ||||||
Cost of revenue (excluding depreciation expense) | 152,226 | 149,796 | 302,022 | |||||||||
Gross profit | 65,584 | 68,310 | 133,894 | |||||||||
% of revenues | 30.1 | % | 31.3 | % | 30.7 | % | ||||||
Other operating expenses | 44,358 | 42,486 | 86,844 | |||||||||
Bad debt expense | 7,164 | 6,223 | 13,387 | |||||||||
General and administrative expenses | 9,479 | 10,025 | 19,504 | |||||||||
Restructuring, acquisition, integration, and other expenses, net | 3,223 | 3,911 | 7,134 | |||||||||
Depreciation and amortization expense | 6,988 | 6,789 | 13,777 | |||||||||
Interest expense, net | 12,744 | 12,715 | 25,459 | |||||||||
Loss on extinguishment of debt | - | 13,453 | 13,453 | |||||||||
Loss on dispositions | - | 685 | 685 | |||||||||
Loss from continuing operations, before income taxes | (18,372 | ) | (27,977 | ) | (46,349 | ) | ||||||
Income tax expense | 619 | 718 | 1,337 | |||||||||
Loss from continuing operations, net of income taxes | (18,991 | ) | (28,695 | ) | (47,686 | ) | ||||||
Loss from discontinued operations, net of income taxes | (437 | ) | (503 | ) | (940 | ) | ||||||
Net loss | $ | (19,428 | ) | $ | (29,198 | ) | $ | (48,626 | ) | |||
Accrued dividends on preferred stock | (2,214 | ) | (2,303 | ) | (4,517 | ) | ||||||
Deemed dividends on preferred stock | (174 | ) | (175 | ) | (349 | ) | ||||||
Loss attributable to common stockholders | $ | (21,816 | ) | $ | (31,676 | ) | $ | (53,492 | ) | |||
Loss per common share: | ||||||||||||
Denominator - Basic and Diluted: | ||||||||||||
Weighted average number of common shares outstanding | 118,783 | 121,189 | 119,993 | |||||||||
Loss from continuing operations, basic and diluted | $ | (0.18 | ) | $ | (0.26 | ) | $ | (0.44 | ) | |||
Income from discontinued operations, basic and diluted | - | - | (0.01 | ) | ||||||||
Net loss per common share, basic and diluted | $ | (0.18 | ) | $ | (0.26 | ) | $ | (0.45 | ) | |||
Schedule 7 | ||||||||||||||||||||
BIOSCRIP, INC. AND SUBSIDIARIES | ||||||||||||||||||||
QUARTERLY CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||||||
(in thousands, except per share amounts) | ||||||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||||||
3/31/2016 | 6/30/2016 | 9/30/2016 | 12/31/2016 | 12/31/2016 | ||||||||||||||||
Net revenue | $ | 238,462 | $ | 232,462 | $ | 224,542 | $ | 240,123 | $ | 935,589 | ||||||||||
Cost of revenue (excluding depreciation expense) | 174,230 | 168,298 | 161,957 | 165,473 | 669,958 | |||||||||||||||
Gross profit | 64,232 | 64,164 | 62,585 | 74,650 | 265,631 | |||||||||||||||
% of revenues | 26.9 | % | 27.6 | % | 27.9 | % | 31.1 | % | 28.4 | % | ||||||||||
Other operating expenses | 39,658 | 40,619 | 42,729 | 47,712 | 170,718 | |||||||||||||||
Bad debt expense | 7,592 | 4,279 | 7,727 | 7,201 | 26,799 | |||||||||||||||
General and administrative expenses | 11,051 | 9,414 | 9,948 | 8,812 | 39,225 | |||||||||||||||
Change in fair value of equity linked liabilities | - | - | - | (10,450 | ) | (10,450 | ) | |||||||||||||
Restructuring, acquisition, integration, and other expenses, net | 2,667 | 4,291 | 2,368 | 6,533 | 15,859 | |||||||||||||||
Depreciation and amortization expense | 4,538 | 4,252 | 4,166 | 8,595 | 21,551 | |||||||||||||||
Interest expense, net | 9,412 | 9,469 | 9,331 | 10,023 | 38,235 | |||||||||||||||
(Gain) on dispositions | (939 | ) | - | (3,015 | ) | - | (3,954 | ) | ||||||||||||
Loss from continuing operations, before income taxes | (9,747 | ) | (8,160 | ) | (10,669 | ) | (3,776 | ) | (32,352 | ) | ||||||||||
Income tax expense | 23 | 149 | 421 | 1,422 | 2,015 | |||||||||||||||
Loss from continuing operations, net of income taxes | (9,770 | ) | (8,309 | ) | (11,090 | ) | (5,198 | ) | (34,367 | ) | ||||||||||
Income (loss) from discontinued operations, net of income taxes | 233 | 75 | (174 | ) | (7,273 | ) | (7,139 | ) | ||||||||||||
Net loss | $ | (9,537 | ) | $ | (8,234 | ) | $ | (11,264 | ) | $ | (12,471 | ) | $ | (41,506 | ) | |||||
Accrued dividends on preferred stock | (1,998 | ) | (2,056 | ) | (2,138 | ) | (2,200 | ) | (8,392 | ) | ||||||||||
Deemed dividends on preferred stock | (172 | ) | (173 | ) | (173 | ) | (174 | ) | (692 | ) | ||||||||||
Loss attributable to common stockholders | $ | (11,707 | ) | $ | (10,463 | ) | $ | (13,575 | ) | $ | (14,845 | ) | $ | (50,590 | ) | |||||
Loss per common share: | ||||||||||||||||||||
Denominator - Basic and Diluted: | ||||||||||||||||||||
Weighted average number of common shares outstanding | 68,771 | 73,186 | 114,826 | 117,683 | 93,740 | |||||||||||||||
Loss from continuing operations, basic and diluted | $ | (0.17 | ) | $ | (0.14 | ) | $ | (0.12 | ) | $ | (0.06 | ) | $ | (0.46 | ) | |||||
Income from discontinued operations, basic and diluted | - | - | - | (0.06 | ) | (0.08 | ) | |||||||||||||
Net loss per common share, basic and diluted | $ | (0.17 | ) | $ | (0.14 | ) | $ | (0.12 | ) | $ | (0.12 | ) | $ | (0.54 | ) | |||||
Investor Contacts: Stephen Deitsch Chief Financial Officer & Treasurer T: (720) 697-5200 stephen.deitsch@bioscrip.comDavid Clair ICR, Inc. T: (646) 277-1266 david.clair@icrinc.com